Author:
Nakamaru Ryo, ,Yamamoto Koichi,Akasaka Hiroshi,Rakugi Hiromi,Kurihara Isao,Yoneda Takashi,Ichijo Takamasa,Katabami Takuyuki,Tsuiki Mika,Wada Norio,Yamada Tetsuya,Kobayashi Hiroki,Tamura Kouichi,Ogawa Yoshihiro,Kawashima Junji,Inagaki Nobuya,Fujita Megumi,Watanabe Minemori,Kamemura Kohei,Okamura Shintaro,Tanabe Akiyo,Naruse Mitsuhide
Abstract
AbstractAlthough adrenalectomy (ADX) is an established treatment for unilateral primary aldosteronism (uPA), the influence of age on the surgical outcomes is poorly understood. Therefore, we aimed to elucidate how age affects the clinical outcomes after treatments. We analyzed 153 older (≥ 65 years) and 702 younger patients (< 65 years) with uPA, treated either with ADX or mineralocorticoid receptor antagonist (MRA) in the Japan PA Study, and compared the estimated glomerular filtration rate (eGFR) or blood pressure over a 36-month period after treatments. ADX-treated patients showed severer biochemical indicators than MRA-treated patients. During 6 and 36 months, the eGFR decreased more prominently in older but not in younger patients with ADX than in those with MRA, which remained significant after adjustment with the inverse probability of treatment weighting (IPTW). There was a significant interaction between the age-groups and the treatment choices in the change of the eGFR with IPTW-adjusted analysis. The post-treatment dose of antihypertensive medication was lower in younger and higher in older patients with ADX than those with MRA. The clinical benefit of ADX differed between younger and older patients with uPA. These findings indicate the need for further validation on whether ADX can benefit older patients with uPA.
Funder
the National Center for Global Health and Medicine
the Japan Agency for Medical Research and Development
Publisher
Springer Science and Business Media LLC
Cited by
7 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献